Karuna Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2018 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Karuna Therapeutics, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2018 to 2023.
- Karuna Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending December 31, 2023 was -$113M, a 50.2% decline year-over-year.
- Karuna Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending December 31, 2023 was -$433M, a 57.5% decline year-over-year.
- Karuna Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$433M, a 57.5% decline from 2022.
- Karuna Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$275M, a 91.2% decline from 2021.
- Karuna Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$144M, a 110% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)